Capricor Therapeutics (CAPR) Accumulated Expenses (2010 - 2026)

Capricor Therapeutics' Accumulated Expenses history runs 11 years deep, the most recent figure standing at $3.8 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 10.34% year-over-year to $3.8 million in Q1 2026; TTM through Mar 2026 was $3.8 million, a 10.34% decrease from a year earlier, with the FY2025 full-year figure at $15.6 million, up 509.5% from the prior year.
• Accumulated Expenses eased to $3.8 million in Q1 2026 per CAPR's latest filing, from $15.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $15.6 million in Q4 2025 and bottomed at $2.6 million in Q4 2024.
• The 3-year median for Accumulated Expenses is $4.2 million (2025), against an average of $6.7 million.
• Across the five-year window, Accumulated Expenses soared 509.5% in 2025 and retreated 10.34% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $2.6 million in 2024, then surged by 509.5% to $15.6 million in 2025, then sank by 75.56% to $3.8 million in 2026.
• Per Business Quant, the three latest CAPR Accumulated Expenses figures stand at $3.8 million (Q1 2026), $15.6 million (Q4 2025), and $9.9 million (Q3 2025).